PRIMMUNE THERAPEUTICS
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
PRIMMUNE THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.primmunerx.com
Total Employee:
1+
Status:
Active
Total Funding:
48.33 M USD
Similar Organizations
Combinati
Combinati is a biotechnology company based in Palo Alto.
Congruence Therapeutics
Congruence Therapeutics operates as a biotechnology company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Faze Medicines
Faze Medicines is a biotechnology company.
Immunicom
Immunicom is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Libra Therapeutics
Libra Therapeutics is a biotechnology company.
Neomorph
Neomorph is a biotechnology company.
RubrYc Therapeutics
RubrYc Therapeutics is a biotechnology company.
Telum Therapeutics
Telum Therapeutics is a biotechnology company.
Current Advisors List
Board_member
2020-03-02
Board_member
2021-01-12
Board_member
2018-08-01
Board_member
2020-10-01
Board_member
2020-10-01
Current Employees Featured
James Appleman Sr. Vice-President, R&D / CSO / Co-founder / Director @ Primmune Therapeutics
Sr. Vice-President, R&D / CSO / Co-founder / Director
2016-03-01
Paulo Rangel Chief Business Officer and Co-founder @ Primmune Therapeutics
Chief Business Officer and Co-founder
2019-03-01
Founder
Investors List
Bioqube Ventures
Bioqube Ventures investment in Series A - Primmune Therapeutics
BioRock Ventures Name
BioRock Ventures Name investment in Series A - Primmune Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series A - Primmune Therapeutics
Oberland Capital
Oberland Capital investment in Series A - Primmune Therapeutics
Charlie McDermott
Charlie McDermott investment in Series A - Primmune Therapeutics
Polaris Partners
Polaris Partners investment in Series A - Primmune Therapeutics
BioBrit
BioBrit investment in Series A - Primmune Therapeutics
CAM Capital
CAM Capital investment in Series A - Primmune Therapeutics
Charlie McDermott
Charlie McDermott investment in Seed Round - Primmune Therapeutics
CAM Capital
CAM Capital investment in Seed Round - Primmune Therapeutics
Official Site Inspections
http://www.primmunerx.com
- Host name: 152.0.198.104.bc.googleusercontent.com
- IP address: 104.198.0.152
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Primmune Therapeutics"
Primmune Therapeutics - Crunchbase Company Profile …
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response …See details»
Team - Primmune
Stephen E. Webber, Ph.D., is Vice President of Medicinal Chemistry and cofounder of Primmune Therapeutics. Dr. Webber was previously Executive Director of Medicinal Chemistry at Polaris …See details»
Primmune Therapeutics, Inc. Company Profile | Carlsbad, CA ...
Find company research, competitor information, contact details & financial data for Primmune Therapeutics, Inc. of Carlsbad, CA. Get the latest business insights from Dun & Bradstreet.See details»
Primmune Therapeutics - PitchBook
Www.primmunerx.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. JLABS San Diego; 3210 Merryfield Row; San Diego, CA …See details»
Advisors - Primmune
Dr. McClure is a consulting Chief Medical Officer (CMO) of Primmune Therapeutics. Dr. McClure has been a CMO at multiple companies over the past nearly seven years and has more than 20 years of clinical and drug …See details»
Primmune Therapeutics - LinkedIn
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and ...See details»
Primmune Therapeutics - Overview, News & Similar companies
Mar 20, 2024 Primmune Therapeutics contact info: Phone number: (858) 205-2281 Website: www.primmunerx.com What does Primmune Therapeutics do? Primmune Therapeutics is …See details»
Primmune Therapeutics, Inc. - VentureRadar
"Primmune is a biopharmaceutical company focused on developing innovative treatments for virally-mediated cancers. Their lead clinical candidate, PRTX007, is an orally administered …See details»
Primmune Therapeutics, Inc. - VentureRadar
Primmune is a biopharmaceutical company focused on developing innovative treatments for virally-mediated cancers. Their lead clinical candidate,... ... Find out more ...See details»
Primmune Therapeutics, Inc. - BIO CEO & Investor Conference | BIO
Feb 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ...See details»
Primmune Therapeutics Receives $8.4 Million in Second Tranche …
Nov 4, 2021 For more information, please visit https://www.primmunerx.com. Contacts. Media: Cammy Duong ICR Westwicke Cammy.Duong@westwicke.com 203-682-8380 Release …See details»
Primmune Therapeutics Announces $27.4 Million Series A Financing
Oct 27, 2020 SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel orally …See details»
Primmune Therapeutics Announces the Selection of PRTX007 as Its ...
Mar 31, 2020 For more information, please visit: www.primmunerx.com. Media Contact: Cammy Duong Canale Communications Tel: 619-849-5389 [email protected] SOURCE Primmune …See details»
Primmune Therapeutics Strengthens Leadership Team with Key …
Feb 5, 2021 Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as …See details»
Primmune Therapeutics Strengthens Leadership Team with Key …
Feb 5, 2021 Primmune Therapeutics strengthens leadership team with key appointments to COO; SVP, Global Manufacturing and Senior Advisor, Commercial Development.See details»
Primmune Therapeutics Presents Data from Phase 1 Study …
Apr 8, 2022 Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual …See details»
Primmune Therapeutics Provides Update on Phase 1 Healthy …
Nov 2, 2021 SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally …See details»
Primmune Therapeutics Presents Clinical Data from Phase 1 Study ...
Nov 10, 2023 — PRTX007 demonstrated a favorable safety profile for all analyzed cohorts with no serious adverse events (SAEs) observed — — Well-controlled activation of innate and …See details»
Primmune Therapeutics Announces Presentation at the 2019 …
SAN DIEGO, November 6, 2019 – Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) …See details»